Key result
Clozapine-associated SCD is linked to high doses, rapid titration, valproate, benzodiazepines, and metabolic comorbidities.
Why the study?
Clozapine carries serious cardiac risks including sudden cardiac death, but specific risk factors for SCD in clozapine-treated patients remain poorly defined.
What are the risk factors for sudden cardiac death or sudden unexplained death in patients treated with clozapine?
Systematic Review (n=498)
What are the risk factors for sudden cardiac death or sudden unexplained death in patients treated with clozapine?
Clozapine-associated sudden cardiac death is multifactorial, driven by high doses, rapid titration, drug interactions, and metabolic/lifestyle factors, highlighting the need for gradual titration and multidisciplinary surveillance.
Answers are grounded in this paper and cite their sources.
Supports enhanced cardiac monitoring for clozapine-treated patients with emerging risk factors; leaves open the need for prospective validation in larger cohorts.
BACKGROUND: Clozapine is the gold-standard treatment for treatment-resistant schizophrenia but carries serious cardiac risks, including sudden cardiac death (SCD). Specific risk factors for SCD in clozapine-treated patients remain poorly defined. AIMS: To systematically identify and synthesise evidence on risk factors for SCD and sudden unexplained death (SUD) in clozapine-treated patients, to guide clinical monitoring. METHOD: We conducted a systematic review following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines (PROSPERO, no. CRD420250646384). Five databases were searched from inception to 13 October 2025. Studies reporting SCD or SUD in clozapine-treated patients were included without restrictions on study design, demographics or diagnosis. Two reviewers independently screened studies and extracted data. Quality was assessed using Joanna Briggs Institute checklists and Risk Of Bias In Non-randomised Studies of Exposures tools. Given study heterogeneity, we performed structured narrative synthesis. RESULTS: Twenty-one studies (1989-2023) were included, comprising 498 cases of SCD/SUD in clozapine-treated patients. Risk factors were grouped into four categories: treatment intensity (high doses (≥525 mg/day), rapid titration), drug interactions (valproate, benzodiazepines, polypharmacy), lifestyle factors (smoking, obesity, diabetes, substance use) and monitoring. Two patterns emerged: early inflammatory myocarditis (weeks 2-6) and late-onset cardiomyopathy (months-years). CONCLUSIONS: Clozapine-associated SCD appears multifactorial. These findings suggest a role for gradual titration, avoidance of high-risk co-medications, baseline biomarker monitoring and ongoing management of metabolic and cardiovascular risk factors. Increased multidisciplinary surveillance may help identify patients at higher risk and inform clinical decision-making in clozapine-treated patients.
No takes yet. Share an insight, caveat, or question.
Easwar et al. (2026) conducted a systematic review in Schizophrenia or schizoaffective disorder treated with clozapine (n=498). Clozapine was evaluated on Risk factors for sudden cardiac death (SCD) or sudden unexplained death (SUD). Clozapine-associated sudden cardiac death is multifactorial, with risk increased by high doses, rapid titration, concomitant valproate or benzodiazepines, and metabolic comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: